Abstract 528P
Background
Precision medicine has been increasingly practiced to select best-fit systemic treatment for advanced and metastatic (a/m) NSCLC. Though new treatment options help improve survival outcomes, they have led to increased financial burdens. In Hong Kong, limited financial assistance programs place the majority of treatment cost on patients. Our study aims to identify gaps in accessing standard-of-care (SOC) treatments and its determinants.
Methods
This prospective, territory-wide cohort study enrolled newly diagnosed a/m NSCLC patients from seven public oncology centers in Hong Kong since Mar 2021. Data on genomic landscape, treatment patterns and socioeconomic status (SES) of NSCLC patients were collected. Provision of SES data was voluntary. Patients were dichotomized into with or without druggable mutations. Proportion of patients receiving SOC were reported and analyzed in relation with SES parameters.
Results
Among 350 patients with SES data, 194 (55.5%) paid out-of-pocket costs for treatments, 110 (31.5%) were partially reimbursed by means-tested subsidy and 34 (9.7%) were fully reimbursed in employee remuneration package. Household income (HI) of 215 patients (60.9%) is less than 23000 USD/year, 95 (26.9%) between 23001-55300 USD/year, and 43 (12.1%) above 55301 USD/year. About 50% of patients had at least 2 children, lived with family members and received secondary education or above. For patients with druggable mutation (n=259), 152 (58.7%) received corresponding targeted treatments. In multivariate analyses (MVA), patients with HI >= 23001 USD/yr is significantly more likely to follow SOC than those with lower income. Self-financed patients are significantly more likely to receive targeted therapies than those with subsidy (OR: 3.73, p=0.004). For patients without druggable mutation (n=77), 32 (52%) received immunotherapy alone or combination. In MVA, patients with HI above 55301 USD/year are more likely to receive immunotherapy as part of treatment than those with lower income (OR: 11.90, p=0.08).
Conclusions
Patients with HI below 55301 USD/year is at risk of deprivation to accessing SOC treatment. Societal efforts are needed to secure equitable access to cancer treatment to all.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Hong Kong.
Funding
Innovation and Technology Commission (HKSAR) & Roche.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract